Clinical Trial Update: ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update evaluating ctDNA-guided use of cetuximab or bevacizumab in combination with trifluridine/tipiracil for RAS/BRAF wild-type metast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Avastin (bevacizumab)
• ERBITUX (cetuximab)
• Lonsurf (trifluridine/tipiracil)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Colorectal Cancer Metastatic | Phase 1, Phase 2 | Status: RECRUITING